Literature DB >> 12937895

Aberrant p38 mitogen-activated protein kinase signalling in skeletal muscle from Type 2 diabetic patients.

H A Koistinen1, A V Chibalin, J R Zierath.   

Abstract

AIMS/HYPOTHESIS: p38 mitogen activated protein kinase (MAPK) is generally thought to facilitate signal transduction to genomic, rather than metabolic responses. However, recent evidence implicates a role for p38 MAPK in the regulation of glucose transport; a site of insulin resistance in Type 2 diabetes. Thus we determined p38 MAPK protein expression and phosphorylation in skeletal muscle from Type 2 diabetic patients and non-diabetic subjects.
METHODS: In vitro effects of insulin (120 nmol/l) or AICAR (1 mmol/l) on p38 MAPK expression and phosphorylation were determined in skeletal muscle from non-diabetic (n=6) and Type 2 diabetic (n=9) subjects.
RESULTS: p38 MAPK protein expression was similar between Type 2 diabetic patients and non-diabetic subjects. Insulin exposure increased p38 MAPK phosphorylation in non-diabetic, but not in Type 2 diabetic patients. In contrast, basal phosphorylation of p38 MAPK was increased in skeletal muscle from Type 2 diabetic patients. CONCLUSION/
INTERPRETATION: Insulin increases p38 MAPK phosphorylation in skeletal muscle from non-diabetic subjects, but not in Type 2 diabetic patients. However, basal p38 MAPK phosphorylation is increased in skeletal muscle from Type 2 diabetic patients. Thus, aberrant p38 MAPK signalling might contribute to the pathogenesis of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937895     DOI: 10.1007/s00125-003-1196-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  33 in total

1.  Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients.

Authors:  J W Ryder; J Yang; D Galuska; J Rincón; M Björnholm; A Krook; S Lund; O Pedersen; H Wallberg-Henriksson; J R Zierath; G D Holman
Journal:  Diabetes       Date:  2000-04       Impact factor: 9.461

2.  A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle.

Authors:  J Mu; J T Brozinick; O Valladares; M Bucan; M J Birnbaum
Journal:  Mol Cell       Date:  2001-05       Impact factor: 17.970

3.  Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  P Arner; T Pollare; H Lithell; J N Livingston
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

4.  The search for physiological substrates of MAP and SAP kinases in mammalian cells.

Authors:  P Cohen
Journal:  Trends Cell Biol       Date:  1997-09       Impact factor: 20.808

5.  Decreased insulin receptor tyrosine kinase activity and plasma cell membrane glycoprotein-1 overexpression in skeletal muscle from obese women with gestational diabetes mellitus (GDM): evidence for increased serine/threonine phosphorylation in pregnancy and GDM.

Authors:  J Shao; P M Catalano; H Yamashita; I Ruyter; S Smith; J Youngren; J E Friedman
Journal:  Diabetes       Date:  2000-04       Impact factor: 9.461

6.  Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients.

Authors:  A Krook; M Björnholm; D Galuska; X J Jiang; R Fahlman; M G Myers; H Wallberg-Henriksson; J R Zierath
Journal:  Diabetes       Date:  2000-02       Impact factor: 9.461

7.  Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients.

Authors:  Bengt Isaksson; Lisa Strömmer; Helmut Friess; Markus W Büchler; Margery K Herrington; Feng Wang; Juleen R Zierath; Harriet Wallberg-Henriksson; Jörgen Larsson; Johan Permert
Journal:  Pancreas       Date:  2003-03       Impact factor: 3.327

8.  Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM.

Authors:  O Pedersen; J F Bak; P H Andersen; S Lund; D E Moller; J S Flier; B B Kahn
Journal:  Diabetes       Date:  1990-07       Impact factor: 9.461

9.  An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects.

Authors:  G L Dohm; E B Tapscott; W J Pories; D J Dabbs; E G Flickinger; D Meelheim; T Fushiki; S M Atkinson; C W Elton; J F Caro
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

10.  Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects.

Authors:  L J Goodyear; F Giorgino; L A Sherman; J Carey; R J Smith; G L Dohm
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more
  32 in total

1.  Differential regulation of CIDEA and CIDEC expression by insulin via Akt1/2- and JNK2-dependent pathways in human adipocytes.

Authors:  Minoru Ito; Michiaki Nagasawa; Naoki Omae; Tomohiro Ide; Yunike Akasaka; Koji Murakami
Journal:  J Lipid Res       Date:  2011-06-02       Impact factor: 5.922

Review 2.  Insulin signaling defects in type 2 diabetes.

Authors:  Ying Leng; Håkan K R Karlsson; Juleen R Zierath
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  A sustained increase in plasma NEFA upregulates the Toll-like receptor network in human muscle.

Authors:  Sophie E Hussey; Helen Lum; Andrea Alvarez; Yolanda Cipriani; Jesús Garduño-Garcia; Luis Anaya; John Dube; Nicolas Musi
Journal:  Diabetologia       Date:  2013-12-14       Impact factor: 10.122

4.  Regulation of Adipose Tissue Inflammation and Insulin Resistance by MAPK Phosphatase 5.

Authors:  Yongliang Zhang; Thang Nguyen; Peng Tang; Norman J Kennedy; Huipeng Jiao; Mingliang Zhang; Joseph M Reynolds; Anja Jaeschke; Natalia Martin-Orozco; Yeonseok Chung; Wei-min He; Chen Wang; Weiping Jia; Baoxue Ge; Roger J Davis; Richard A Flavell; Chen Dong
Journal:  J Biol Chem       Date:  2015-04-28       Impact factor: 5.157

5.  p38 MAPK activation upregulates proinflammatory pathways in skeletal muscle cells from insulin-resistant type 2 diabetic patients.

Authors:  Audrey E Brown; Jane Palsgaard; Rehannah Borup; Peter Avery; David A Gunn; Pierre De Meyts; Stephen J Yeaman; Mark Walker
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-11-04       Impact factor: 4.310

6.  TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle.

Authors:  Yi-Ping Li; Yuling Chen; Joseph John; Jennifer Moylan; Bingwen Jin; Douglas L Mann; Michael B Reid
Journal:  FASEB J       Date:  2005-03       Impact factor: 5.191

7.  Regeneration of diabetic axons is enhanced by selective knockdown of the PTEN gene.

Authors:  Bhagat Singh; Vandana Singh; Anand Krishnan; Kurien Koshy; Jose A Martinez; Chu Cheng; Chris Almquist; Douglas W Zochodne
Journal:  Brain       Date:  2014-02-27       Impact factor: 13.501

8.  Oxidant stress-induced loss of IRS-1 and IRS-2 proteins in rat skeletal muscle: role of p38 MAPK.

Authors:  Tara L Archuleta; Andrew M Lemieux; Vitoon Saengsirisuwan; Mary K Teachey; Katherine A Lindborg; John S Kim; Erik J Henriksen
Journal:  Free Radic Biol Med       Date:  2009-08-22       Impact factor: 7.376

9.  Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle.

Authors:  K Eckardt; H Sell; A Taube; M Koenen; B Platzbecker; A Cramer; A Horrighs; M Lehtonen; N Tennagels; J Eckel
Journal:  Diabetologia       Date:  2008-12-17       Impact factor: 10.122

10.  Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis.

Authors:  Grzegorz Sumara; Ivan Formentini; Stephan Collins; Izabela Sumara; Renata Windak; Bernd Bodenmiller; Reshma Ramracheya; Dorothée Caille; Huiping Jiang; Kenneth A Platt; Paolo Meda; Rudolf Aebersold; Patrik Rorsman; Romeo Ricci
Journal:  Cell       Date:  2009-01-08       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.